02 Aug Enalapril 10mg Arya
| Company name & Address: | Registration number | Batch number(s) | Expiry date | Pack size | First release date | Re-call Classification | Recall date |
| Arya Pharma Pty Ltd
Pharma HQ, Corner Barbara and North Reef Road, Elandsfontein, Germiston, Gauteng, 1601. |
37/7.1.3/0328 |
GQQ24066
|
GQQ24066 (Sep-2026)
|
28’s |
GQQ24066 (Jan-2025) GQQ24064 (Jan-2025) GQQ24067 (July-2025) GQQ24053 (Jan-2025) |
Class II Type A |
29 July 2026 |
Brief description of the problem (reason for recall)
Quality defect: This recall is initiated due to out-of-specification results observed during post-marketing surveillance studies.
Advice for health professionals and distributors:
Arya kindly request that you immediately refrain from selling or distributing the affected batches listed above. Additionally, please inform your patients to return any affected stock to your dispensary. Please quarantine all remaining stock and return it to your supplying warehouse or distributor with immediate effect. Arya Pharma Pty Ltd will arrange for the collection of all returned stock, and appropriate credit will be issued. Kindly retain this recall letter in a prominent location for one month, as additional stock may still be in transit.
For further product information, please call Arya Pharma Pty Ltd on 010 060 0740/4.
Proposed action taken and its urgency: A SAHPRA approved recall letter was distributed to all distribution points, and the recall process was initiated.
Reporting side effects
Public and healthcare professionals are encouraged to report any side effects after using a health product or after immunisation by using the Med Safety App. Your report will contribute to our monitoring of these health products.